MannKind Corporation Stock News

MannKind Corporation (NASDAQ:MNKD) shareholders should be happy to see the share price up 18% in the last week. But...

It has been a rough five years for investors of diabetes-focused biotech MannKind (MNKD). Over the period, shares of the company have declined by 94%. However, according to H.C. Wainwright analyst Or

Cuts for some CEOs but no change for others — and a split between sectors

Q1 2020 MannKind Corp Earnings Call

MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million; +58% vs. 1Q 20191Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019Non-GAAP Net Cash.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.

MannKind Corporation (MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (East

United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 million year-over-year while

Some public companies reported receiving coronavirus relief loans, prompting questions about how large companies are tapping the emergency fund intended for struggling mom-and-pop businesses.